Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 23, 2025, titled "Dr. Reddy s announces its intention to appoint M/s. DeloitteHaskins & Sells LLP as Statutory Auditors effective from FY 2026-27".
Press Release Jul 23 2025
Filed with NSE ·
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call6ix hasn’t read this filing yet.
Dr. Reddy's Laboratories Ltd. on 6ix
In the deck
Earlier from Dr. Reddy's Laboratories
- Dr. Reddy’s Q1FY26 Financial Results
- Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan
- Press Release Jul 15 2025
- Press Release Jun 05 2025
- Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Later from Dr. Reddy's Laboratories
- Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
- Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Press Release Sep 16 2025
- Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
- Press Release Oct 13 2025
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories